Compare Enveric Biosciences Inc (ENVB) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Otis Worldwide Corp — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Otis Worldwide Corp trades at $73.45 (market cap $27.74B). The key difference: Otis Worldwide Corp is far larger — about 4474.2× Enveric Biosciences Inc's market cap, and Otis Worldwide Corp pays a 2.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | OTIS | |
|---|---|---|
Market Cap | $6.20M | $27.74B |
Sector | Health | Industrials |
52-Week High | $17.40 | $93.62 |
52-Week Low | $1.27 | $69.34 |
Enterprise Value | $1.30M | $35.77B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Otis Worldwide (OTIS) trades at $73.99, up 0.22% with a bullish technical signal. The company maintains stable revenue around $14.4B but faces margin pressure despite strong service segment growth. Recent Q2 2026 earnings beat estimates but included guidance cuts, reflecting ongoing challenges in new equipment demand. Analyst consensus remains divided with a $92.50 price target suggesting 25% upside potential.
The investment case hinges on service segment momentum offsetting equipment weakness, but margin compression and elevated debt levels pose risks. With mixed analyst ratings and recent institutional selling, the stock offers value if service margins improve, though execution risks remain elevated in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
